ImmuPharma (LON:IMM) Stock Price Down 6.1% – Should You Sell?

ImmuPharma plc (LON:IMM)’s share price dropped 6.1% during mid-day trading on Thursday . The stock traded as low as GBX 10 ($0.13) and last traded at GBX 10.43 ($0.14). Approximately 3,312,566 shares traded hands during trading, a decline of 61% from the average daily volume of 8,523,676 shares. The stock had previously closed at GBX 11.10 ($0.15).

ImmuPharma Trading Down 8.3%

The company has a market capitalization of £50.87 million, a P/E ratio of -1,143.82 and a beta of 1.53. The business has a 50 day moving average price of GBX 4.84 and a 200 day moving average price of GBX 3.44.

ImmuPharma (LON:IMM) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.